461 related articles for article (PubMed ID: 23525426)
1. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
Ayaori M; Iwakami N; Uto-Kondo H; Sato H; Sasaki M; Komatsu T; Iizuka M; Takiguchi S; Yakushiji E; Nakaya K; Yogo M; Ogura M; Takase B; Murakami T; Ikewaki K
J Am Heart Assoc; 2013 Jan; 2(1):e003277. PubMed ID: 23525426
[TBL] [Abstract][Full Text] [Related]
2. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Nakamura K; Oe H; Kihara H; Shimada K; Fukuda S; Watanabe K; Takagi T; Yunoki K; Miyoshi T; Hirata K; Yoshikawa J; Ito H
Cardiovasc Diabetol; 2014 Jul; 13():110. PubMed ID: 25074318
[TBL] [Abstract][Full Text] [Related]
3. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
Oe H; Nakamura K; Kihara H; Shimada K; Fukuda S; Takagi T; Miyoshi T; Hirata K; Yoshikawa J; Ito H;
Cardiovasc Diabetol; 2015 Jun; 14():83. PubMed ID: 26084668
[TBL] [Abstract][Full Text] [Related]
4. Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study.
Maruhashi T; Higashi Y; Kihara Y; Yamada H; Sata M; Ueda S; Odawara M; Terauchi Y; Dai K; Ohno J; Iida M; Sano H; Tomiyama H; Inoue T; Tanaka A; Murohara T; Node K;
Cardiovasc Diabetol; 2016 Sep; 15(1):134. PubMed ID: 27624168
[TBL] [Abstract][Full Text] [Related]
5. Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.
Widlansky ME; Puppala VK; Suboc TM; Malik M; Branum A; Signorelli K; Wang J; Ying R; Tanner MJ; Tyagi S
Vasc Med; 2017 Jun; 22(3):189-196. PubMed ID: 28145158
[TBL] [Abstract][Full Text] [Related]
6. Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study.
Ida S; Murata K; Betou K; Kobayashi C; Ishihara Y; Imataka K; Uchida A; Monguchi K; Kaneko R; Fujiwara R; Takahashi H
Cardiovasc Diabetol; 2016 Nov; 15(1):153. PubMed ID: 27809903
[TBL] [Abstract][Full Text] [Related]
7. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
8. DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.
Fujita H; Taniai H; Murayama H; Ohshiro H; Hayashi H; Sato S; Kikuchi N; Komatsu T; Komatsu K; Komatsu K; Narita T; Yamada Y
Endocr J; 2014; 61(2):159-66. PubMed ID: 24225429
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
Capuano A; Sportiello L; Maiorino MI; Rossi F; Giugliano D; Esposito K
Drug Des Devel Ther; 2013; 7():989-1001. PubMed ID: 24068868
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial.
Kobayashi K; Yokoh H; Sato Y; Takemoto M; Uchida D; Kanatsuka A; Kuribayashi N; Terano T; Hashimoto N; Sakurai K; Hanaoka H; Ishikawa K; Onishi S; Yokote K;
Diabetes Obes Metab; 2014 Aug; 16(8):761-5. PubMed ID: 24447683
[TBL] [Abstract][Full Text] [Related]
12. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
[TBL] [Abstract][Full Text] [Related]
13. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.
Ueda S; Shimabukuro M; Arasaki O; Node K; Nomiyama T; Morimoto T
Cardiovasc Drugs Ther; 2018 Feb; 32(1):73-80. PubMed ID: 29435776
[TBL] [Abstract][Full Text] [Related]
14. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
Cardiovasc Diabetol; 2020 Jun; 19(1):89. PubMed ID: 32539832
[TBL] [Abstract][Full Text] [Related]
15. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N
Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm.
Devin JK; Pretorius M; Nian H; Yu C; Billings FT; Brown NJ
J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25158865
[TBL] [Abstract][Full Text] [Related]
17. Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus.
Kishimoto S; Kinoshita Y; Matsumoto T; Maruhashi T; Kajikawa M; Matsui S; Hashimoto H; Takaeko Y; Kihara Y; Chayama K; Goto C; Mohamad Yusoff F; Nakashima A; Noma K; Higashi Y
Am J Hypertens; 2019 Jun; 32(7):695-702. PubMed ID: 31045223
[TBL] [Abstract][Full Text] [Related]
18. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
19. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
Jarvis CI; Cabrera A; Charron D
Ann Pharmacother; 2013 Nov; 47(11):1532-9. PubMed ID: 24285765
[TBL] [Abstract][Full Text] [Related]
20. Effects of sitagliptin beyond glycemic control: focus on quality of life.
Sakamoto Y; Oyama J; Ikeda H; Kuroki S; Gondo S; Iwamoto T; Uchida Y; Kodama K; Hiwatashi A; Shimomura M; Taguchi I; Inoue T; Node K;
Cardiovasc Diabetol; 2013 Feb; 12():35. PubMed ID: 23432786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
